Tesofensine vs GHK-Cu
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
TesofensineSkin & CosmeticRecovery & RepairAnti-Aging & Longevity
GHK-Cu- Summary
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
- Half-Life
- 8-10 days (exceptionally long; accumulates over weeks)
- 2–4 hours
- Admin Route
- Oral
- SubQ, Topical
- Research
- —
- —
- Typical Dose
- 0.25-0.5 mg per day
- 1–3 mg
- Frequency
- Once daily
- 3–5 times per week
- Key Benefits
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Reduces wrinkles and fine lines
- Improves skin firmness and elasticity
- Accelerates wound healing
- Reduces inflammation and oxidative damage
- Promotes hair growth and thickness
- Supports collagen and elastin production
- May improve overall skin health and appearance
- Resets aged fibroblast behavior
- Anti-fibrotic — reduces scar tissue formation
- Side Effects
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Temporary blue-green discoloration at injection site (from copper — harmless)
- Post-injection sting (brief)
- Skin irritation with topical use (rare)
- Stacks With
- —
- —